Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexpramipexole (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPOWER
  • Sponsors Biogen; Knopp Biosciences
  • Most Recent Events

    • 09 Jul 2019 According to an Knopp Biosciences media release, the analysis of the eosinophil-lowering effects of dexpramipexole seen in this study will be presented at the 11th Biennial Symposium of the International Eosinophil Society.
    • 30 Nov 2017 According to a Cytokinetics media release, retrospective analysis data from EMPOWER, BENEFIT-ALS and Open-Access ALS Clinical Trials (PRO-ACT) database were published in the Journal of the American Medical Association (JAMA) Neurology.
    • 30 Nov 2017 Retrospective data was published in a Cytokinetics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top